ENV-ONC-101: Hedgehog Pathway Inhibitor in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsTaladegib

Condition: Solid Tumors

Sponsor: Endeavor Biomedicines, Inc.

Full Title
ENV-ONC-101: A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Study Treatment
Oral small molecule hedgehog pathway inhibitor taladegib

Eligibility/Info
For patients with an advanced or metastatic solid tumor with a PTCH1 loss of function mutation that have been treated with and are refractory to all available standard of care therapy in their tumor type.

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.